Jeffrey Marx, MD
Chairman of the Department of Ophthalmology Lahey Clinic Inc
Member of the Healthcare Council
Jeffrey Marx, MD, is a Chairman of the Department of Ophthalmology at the Lahey Clinic in Burlington and Associate Clinical Professor of Ophthalmology at Tufts University School of Medicine, Massachusetts. Dr Marx specializes in medical and surgical diseases of the retina including diabetic eye care, macular degeneration and retinal detachment. He is principal or sub principal investigator at Lahey Clinic on studies involving macular degeneration, diabetic retinopathy and vein occlusion. He has received the Achievement Award from the American Academy of Ophthalmology and the Honor Award from the American Society of Retina Specialists. (This is me - Update Profile)
| Unspecified - present | Chairman of the Department of Ophthalmology Lahey Clinic Inc |
|---|---|
| Unspecified - present | Associate Clinical Professor of Ophthalmology Tufts University School of Medicine |
GLG Study Groups with Jeffrey Marx, MD(?)
| Study Group Name | Members |
|---|---|
| Ophthalmologists (US) | 1066 |
| Ophthalmologists who Treat Macular Degeneration (US) | 150 |
| Physicians who Treat Dry Eye (US) | 127 |
| Glaucoma Specialists (US) | 191 |
GLG NewsSM Analyses by Jeffrey Marx, MD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Jeffrey Marx, MD has not published any public GLG News analyses.
View all GLG News in Healthcare
View all GLG News in Healthcare
GLG InstituteSM Seminars with Jeffrey Marx, MD(?)
Jeffrey Marx, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare
View all GLG InstituteSM Seminars in Healthcare
Request a project with Jeffrey Marx, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
40 of the leading 50
global mutual funds
global mutual funds
15 of the leading 20
global banks
global banks
8 of the leading 10
private equity firms
private equity firms
90%+ client subscription renewal rate

